2016
DOI: 10.1016/j.eururo.2015.11.033
|View full text |Cite
|
Sign up to set email alerts
|

Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
52
0
1

Year Published

2016
2016
2021
2021

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 59 publications
(54 citation statements)
references
References 10 publications
1
52
0
1
Order By: Relevance
“…CAIX mAbs have been developed that allow delivery of radioisotopes and cytotoxic drugs to cancer cells [205,206]. A phase II trial of 177 Lu-girentuximab in metastatic clear cell renal carcinoma attained stable disease in 9 of 14 patients [207]. Another inhibitor indisulam, which demonstrated promising preclinical activity [208], has undergone phase II clinical trials for stage IV melanoma, renal clear cell carcinoma and metastatic breast cancer [209], although in advanced NSCLC patients there was little response when it was used as second-line therapy [210].…”
Section: Carbonic Anhydrase IXmentioning
confidence: 99%
“…CAIX mAbs have been developed that allow delivery of radioisotopes and cytotoxic drugs to cancer cells [205,206]. A phase II trial of 177 Lu-girentuximab in metastatic clear cell renal carcinoma attained stable disease in 9 of 14 patients [207]. Another inhibitor indisulam, which demonstrated promising preclinical activity [208], has undergone phase II clinical trials for stage IV melanoma, renal clear cell carcinoma and metastatic breast cancer [209], although in advanced NSCLC patients there was little response when it was used as second-line therapy [210].…”
Section: Carbonic Anhydrase IXmentioning
confidence: 99%
“…After Stillbroer et al [ 57 ] determined the maximum tolerated dose of 177Lu-girentuximab in a phase I study, Muselaers et al [ 58 ] evaluated in 2015, in a phase II non-randomized single-arm trial, the efficacy of 177 Lu-girentuximab. Fourteen metastatic ccRCC patients with evidence of progressive disease were enrolled between April 2011 and August 2014.…”
Section: Evidence Synthesismentioning
confidence: 99%
“…In the phase II clinical trial, stable disease was experienced by 57% of the patients with manageable toxicity, especially low blood cell counts [103]. A randomized, double-blind, placebocontrolled phase III clinical trial evaluated girentuximab as an adjuvant therapy in 864 patients with high risk of postoperative recurrence RCC [104].…”
Section: Immunotherapymentioning
confidence: 99%